v3.26.3
Segment Reporting - Summary of Disaggregated Amounts Research and Development Expenses and Segment Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Primary program research and development expenses [1] $ 18,574     $ 15,414     $ 50,481 $ 46,862
Total other research and development expenses 4,117     4,071     11,936 11,242
Research and development operating expenses excluding non-cash stock-based compensation 22,691     19,485     62,417 58,104
General and administrative expense excluding non-cash stock-based compensation 12,968     7,309     34,653 22,860
Other segment income (expense), net [2] 7,330     2,767     23,431 5,637
Net loss (42,989) $ (40,228) $ (37,284) (29,561) $ (30,401) $ (26,639) (120,501) (86,601)
Payroll and Benefits [Member]                
Segment Reporting [Line Items]                
Total other research and development expenses 3,639     3,514     10,257 9,611
Occupancy and Other Overhead and Operating Costs [Member]                
Segment Reporting [Line Items]                
Total other research and development expenses $ 478     $ 557     $ 1,679 $ 1,631
[1] Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.
[2] Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt (for the nine months ended September 30, 2025), tax credit income, and the change in fair value of the royalty agreement derivative liability.